X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Piramal Healthcare Fact Sheet, Piramal Healthcare Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Piramal Healthcare Fact Sheet   (NCHP)

Here is the latest financial fact sheet of Piramal Healthcare. For more details, see the Piramal Healthcare quarterly results and Piramal Healthcare share price and chart. For a sector overview, read our pharmaceuticals sector report.

PIRAMAL ENTERPRISES Price History

Price Rs 2,622.1
Mkt Cap Rs m 452,461
Vol '000 4.4
P/E X 36.6
P/CF X 30.9
EPS (TTM) Rs 71.7
% ch % 1.3
No. of shares m 172.56
% ch week % -0.2
% ch 1-mth % -7.0
% ch 12-mth % 41.3
52 week H/L Rs 3,065.1/1,800.5
(As on Feb 23, 2018 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

PIRAMAL ENTERPRISES Financials

No. of Mths
Year Ending
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
12
Mar-17
*
5-Yr Chart
Click to enlarge
PIRAMAL ENTERPRISES EQUITY SHARE DATA
High Rs6256489491,0652,095 
Low Rs3954835228051,025 
Sales per share (Unadj.) Rs204.0260.9296.9367.5492.8 
Earnings per share (Unadj.) Rs-13.2-29.1165.252.472.6 
Diluted earnings per shareRs-13.2-29.1165.252.472.6 
Cash flow per share (Unadj.) Rs-1.0-14.7182.067.294.7 
Dividends per share (Unadj.) Rs17.5052.5020.0017.5021.00 
Adj. dividends per shareRs17.5052.5020.0017.5021.00 
Dividend yield (eoy) %3.49.32.71.91.3 
Book value per share (Unadj.) Rs621.4540.2778.0750.4862.5 
Adj. book value per shareRs621.4540.2778.0750.4862.5 
Shares outstanding (eoy) m172.56172.56172.56172.56172.56 
Bonus/Rights/Conversions  ----- 
Price / Sales ratio x2.52.22.52.53.2 
Avg P/E ratio x-38.7-19.54.517.821.5 
P/CF ratio (eoy) x-496.3-38.34.013.916.5 
Price / Book Value ratio x0.81.00.91.21.8 
Dividend payout %-132.9-180.712.133.428.9 
Avg Mkt Cap Rs m87,99797,583126,901161,344269,194 
No. of employees `0003.03.02.43.84.0 
Total wages/salary Rs m7,96511,37012,94816,83117,939 
Avg. sales/employee Rs Th11,828.614,969.221,167.816,763.221,190.3 
Avg. wages/employee Rs Th2,676.53,779.85,350.24,449.04,470.1 
Avg. net profit/employee Rs Th-763.7-1,666.911,776.72,391.63,120.0 
PIRAMAL ENTERPRISES INCOME DATA
Net Sales Rs m35,20245,02751,22663,41585,037 
Other income Rs m1,7932,2132,5422,5172,338 
Total revenues Rs m36,99447,24053,76865,93287,374 
Gross profit Rs m4,3176,3918,85516,77234,991 
Depreciation Rs m2,0962,4692,8992,5553,817 
Interest Rs m5,75010,4965,1069,59120,310 
Profit before tax Rs m-1,736-4,3613,3927,14413,202 
Minority Interest Rs m-56-831,9421,699 
Prior Period Items Rs m-42-311,59300 
Extraordinary Inc (Exp) Rs m-1911426,962457-100 
Tax Rs m2486283,4504952,281 
Profit after tax Rs m-2,273-5,01428,5009,04712,520 
Gross profit margin %12.314.217.326.441.1 
Effective tax rate %-14.3-14.4101.76.917.3 
Net profit margin %-6.5-11.155.614.314.7 
PIRAMAL ENTERPRISES BALANCE SHEET DATA
Current assets Rs m40,87642,32447,70144,92887,590 
Current liabilities Rs m81,51593,50847,999103,802185,578 
Net working cap to sales %-115.4-113.7-0.6-92.8-115.2 
Current ratio x0.50.51.00.40.5 
Inventory Days Days5653474231 
Debtors Days Days6258585648 
Net fixed assets Rs m20,76822,58567,73578,803108,523 
Share capital Rs m345345345345345 
"Free" reserves Rs m105,09189,562133,910129,138148,481 
Net worth Rs m107,23693,211134,255129,484148,826 
Long term debt Rs m11,61026,79636,87374,740144,957 
Total assets Rs m202,521215,045220,026309,797482,394 
Interest coverage x0.70.61.71.71.7 
Debt to equity ratio x0.10.30.30.61.0 
Sales to assets ratio x0.20.20.20.20.2 
Return on assets %1.72.515.36.06.8 
Return on equity %-2.1-5.421.27.08.4 
Return on capital %3.15.121.79.412.0 
Exports to sales %22.721.519.517.90 
Imports to sales %10.49.38.56.90 
Exports (fob) Rs m7,9879,68710,00911,3620 
Imports (cif) Rs m3,6664,2094,3744,3640 
Fx inflow Rs m8,89110,51712,01014,43515,001 
Fx outflow Rs m4,3395,0065,7405,1835,150 
Net fx Rs m4,5525,5106,2709,2539,851 
PIRAMAL ENTERPRISES CASH FLOW
From Operations Rs m -15,705 -16,044 -22,069 -69,562 -100,393 
From Investments Rs m -16,645 14,829 61,771 -6,040 -24,202 
From Financial Activity Rs m 32,807 1,258 -38,646 75,439 135,705 
Net Cashflow Rs m 458 43 1,056 -163 11,110 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 52.9%
Foreign collaborators 0.0%
Indian inst/Mut Fund 4.0%
FIIs 26.6%
ADR/GDR 0.0%
Free float 16.5%
Shareholders 93,274
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF Piramal Tower, Ganpatrao Kadam Marg, Lower Parel, Mumbai - 400 013
E-MAIL complianceofficer.phl@piramal.com WEB www.piramal.com
TELEPHONE (022) 3046 7839 FAX (022) 3046 7855
SECTOR PHARMACEUTICALS GROUP AJAY PIRAMAL
TR AGENT Link Intime India, C13, Pannalal Silk Mills Compd., LBS Marg, Mumbai-78
AUDITOR Price Waterhouse
CHM: Ajay G. Piramal COMP SEC: Leonard D' Souza YEAR OF INC: 1947 BSE CODE: 500302 FV (Rs): 2 DIV YIELD (%): 0.8

More Pharmaceuticals Company Fact Sheets:   LUPIN LTD  INDOCO REMEDIES  DISHMAN PHARMA  PANACEA BIOTECH  GSK PHARMA  

Compare PIRAMAL ENTERPRISES With:   LUPIN LTD  INDOCO REMEDIES  DISHMAN PHARMA  PANACEA BIOTECH  GSK PHARMA  

Compare PIRAMAL ENTERPRISES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Views on news

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES - TEVA PHARMA COMPARISON

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS